233 related articles for article (PubMed ID: 19661132)
21. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
22. Sex hormone-binding globulin selectively modulates estradiol-regulated genes in MCF-7 cells.
Catalano MG; Costantino L; Frairia R; Boccuzzi G; Fortunati N
Horm Metab Res; 2007 Apr; 39(4):288-94. PubMed ID: 17447168
[TBL] [Abstract][Full Text] [Related]
23. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling.
Jiang J; Slivova V; Sliva D
Int J Oncol; 2006 Sep; 29(3):695-703. PubMed ID: 16865287
[TBL] [Abstract][Full Text] [Related]
24. Regulation of estrogen receptors alpha and beta in human breast carcinoma by exogenous leptin in nude mouse xenograft model.
Yu W; Gu JC; Liu JZ; Wang SH; Wang Y; Zhang ZT; Ma XM; Song MM
Chin Med J (Engl); 2010 Feb; 123(3):337-43. PubMed ID: 20193256
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
[TBL] [Abstract][Full Text] [Related]
26. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1.
Choi ES; Shim JH; Jung JY; Kim HJ; Choi KH; Shin JA; Nam JS; Cho NP; Cho SD
Cancer Sci; 2011 Apr; 102(4):742-8. PubMed ID: 21241418
[TBL] [Abstract][Full Text] [Related]
27. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
28. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
29. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
31. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
[TBL] [Abstract][Full Text] [Related]
32. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells.
Rasmussen LM; Frederiksen KS; Din N; Galsgaard E; Christensen L; Berchtold MW; Panina S
Endocr Relat Cancer; 2010 Sep; 17(3):809-22. PubMed ID: 20601496
[TBL] [Abstract][Full Text] [Related]
33. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
35. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
36. Heterotrimeric stimulatory GTP-binding proteins inhibit cisplatin-induced apoptosis by increasing X-linked inhibitor of apoptosis protein expression in cervical cancer cells.
Cho EA; Oh JM; Kim SY; Kim Y; Juhnn YS
Cancer Sci; 2011 Apr; 102(4):837-44. PubMed ID: 21255191
[TBL] [Abstract][Full Text] [Related]
37. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation.
Antalis CJ; Arnold T; Rasool T; Lee B; Buhman KK; Siddiqui RA
Breast Cancer Res Treat; 2010 Aug; 122(3):661-70. PubMed ID: 19851860
[TBL] [Abstract][Full Text] [Related]
38. Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells.
Grzmil M; Kaulfuss S; Thelen P; Hemmerlein B; Schweyer S; Obenauer S; Kang TW; Burfeind P
J Pathol; 2006 Feb; 208(3):340-9. PubMed ID: 16353131
[TBL] [Abstract][Full Text] [Related]
39. Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.
Gallo D; Mantuano E; Fabrizi M; Ferlini C; Mozzetti S; De Stefano I; Scambia G
Endocr Relat Cancer; 2007 Jun; 14(2):317-24. PubMed ID: 17639047
[TBL] [Abstract][Full Text] [Related]
40. Effects of adiponectin on breast cancer cell growth and signaling.
Grossmann ME; Nkhata KJ; Mizuno NK; Ray A; Cleary MP
Br J Cancer; 2008 Jan; 98(2):370-9. PubMed ID: 18182989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
